BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Drug Development

  Oncoceutics Release: ONC201 Trial for Histone Mutant Glioma Begins at NYU

  Oncoceutics announced today that the first patient has been treated in a Phase II clinical trial of ONC201 for patients with recurrent high-grade gliomas that contain a specific mutation called the histone H3 K27M mutation.

  November 7, 2017

   · 

  3 min read
• Drug Development

  AnaptysBio Reports Positive ANB019 Top-line Phase I Clinical Trial Results

  Top-line data demonstrated favorable safety, pharmacokinetics and pharmacodynamic properties that support advancement of ANB019 into patient Phase 2 studies.

  November 7, 2017

   · 

  6 min read
• Business

  Voyager Therapeutics Announces Proposed Offering of Common Stock

  In addition, Voyager intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering.

  November 7, 2017

   · 

  4 min read
• Deals

  Bioclinica Acquires MDDX Research & Informatics Combining Advanced Image Management Cloud Technology With its Scientific and Medical Imaging Leadership

  With the acquisition comes MDDX’s best-in-class, cloud-based image submission technology, which will become the backbone of Bioclinica’s SMART solution.

  November 7, 2017

   · 

  6 min read
• Business

  MRI Interventions Reports 26% Year-Over-Year Increase in Third Quarter Procedures

  Total revenue increased 6% to $1.7 million, from $1.6 million in the same period of 2016, reflecting a 12% increase in disposable sales, offset by lower capital equipment sales.

  November 7, 2017

   · 

  17 min read
• Business

  XOMA Reports Third Quarter 2017 Financial Results

  XOMA made important progress positioning the Company for long-term strategic success.

  November 7, 2017

   · 

  9 min read
• Business

  Akcea Reports Financial Results and Highlights for Third Quarter 2017

  The Company reported an operating loss for the three and nine months ended September 30, 2017 on a GAAP basis of $12.6 million and $83.7 million, respectively.

  November 7, 2017

   · 

  12 min read
• Business

  Flexion Therapeutics Reports Third-Quarter 2017 Financial Results and Recent Business Highlights

  The Company reported a net loss of $34.2 million for the third quarter of 2017, compared to a net loss of $17.8 million for the same period of 2016.

  November 7, 2017

   · 

  12 min read
• Bio NC

  H&A Scientific Celebrates 25th Anniversary, Unveils SLIM 5.0.0 at AAPS in San Diego

  H&A Scientific will introduce version 5.0.0 of SLIM at the American Association of Pharmaceutical Scientists Annual Meeting, Nov. 12-15, in San Diego.

  November 7, 2017

   · 

  2 min read
• Business

  Fulgent Genetics Reports Third Quarter 2017 Financial Results

  Third quarter revenue was $4.5 million, a decrease of 10% year over year from $5.0 million in the third quarter of 2016.

  November 7, 2017

   · 

  12 min read